Spotlight Innovation is a pharmaceutical company. It focuses on acquiring rights to innovative and proprietary therapeutics designed to address unmet medical needs. The Company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; STL-182, an orally-available small molecule for the treatment of spinal muscular atrophy; and products derived from cobra and venom to treat chronic pain. Spotlight Innovation offers SOLX Gold Shunt, an implantable drainage device designed to reduce elevated intraocular pressure associated with refractory glaucoma without creating a bleb.